Revvity (RVTY) stock has been a mixed bag of news lately. The company recently secured a $1.5 Billion unsecured revolving credit facility and announced the FDA clearance for their first Automated Free Testosterone Test. These positive advancements were somewhat offset when Sanford C. Bernstein downgraded the stock rating to 'Market Perform' and the company cut their 2024 revenue forecast citing a slow inspection in biotech spending. High points came when JPMorgan Chase & Co. purchased shares and the company outperformed its competitors on the stock market. However, these victories were soon followed by a stock price fall post the Q3 Earnings report. Revvity closed Q3 2024 with strong EPS and cashflow amid market challenges, but not without insider selling shares causing minor ripples in the market.
Revvity RVTY News Analytics from Tue, 09 May 2023 07:00:00 GMT to Fri, 10 Jan 2025 16:25:56 GMT -
Rating 2
- Innovation 4
- Information 6
- Rumor -2
